Phaseline

Targets › FCGRT

FCGRT (IgG receptor FcRn large subunit p51): drug programs, companies and trials

5 programs from 5 companies in 43 trials: 19 Phase 3, 18 Phase 2, 4 Phase 4, 2 Phase 1; Neurology, Other, Hematology; next expected readout Dec 2026.

Cell surface receptor that transfers passive humoral immunity from the mother to the newborn. Binds to the Fc region of monomeric immunoglobulin gamma and mediates its selective uptake from milk. (UniProt, P55899)

Open in Phaseline: the race on FCGRT, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
argenxEfgartigimod Alfa (PH20)
IgG receptor FcRn large subunit p51 antagonist
FCGRTPhase 4New Onset Generalized Myasthenia Gravis (gMG); Primary Sjogrens Disease; Primary Immune Thrombocytopenia; Myasthenia Gravis, Ocular …Mar 2027
UCB Biopharma SRLRozanolixizumab
IgG receptor FcRn large subunit p51 inhibitor
FCGRTPhase 4Myasthenia Gravis; Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD); Generalized Myasthenia Gravis; Ocular Myasthenia GravisMay 2027
Johnson & Johnson (Janssen)Nipocalimab
IgG receptor FcRn large subunit p51 antagonist
FCGRTPhase 3Hemolytic Disease of the Fetus and Newborn; Myasthenia Gravis; Thrombocytopenia, Neonatal Alloimmune; Sjogrens Syndrome …Dec 2026
Thomas Jefferson UniversityVYVGART Hytrulo
IgG Fc receptor neonatal (FcRn) antagonist; reduces circulating IgG antibodies including a
FCGRTPhase 2Stiff Person SyndromeDec 2027
SanofiBIVV020 (SAR445088)
Neonatal Fc receptor (FcRn) antagonist
FCGRTPhase 2Transplant Rejection–

Conditions

Generalized Myasthenia Gravis (5) Myasthenia Gravis (4) Thrombocytopenia, Neonatal Alloimmune (2) Ocular Myasthenia Gravis (2) Hemolytic Disease of the Fetus and Newborn (1) Sjogrens Syndrome (1) Lupus Erythematosus, Systemic (1) Myositis (1) Polyradiculoneuropathy, Chronic Inflammatory Demyelinating (1) Warm Autoimmune Hemolytic Anemia (1) Healthy (1) Transplant Rejection (1)

Modalities

antibody (2), mixed (1), protein or peptide (1), small molecule (1)

Companies

Johnson & Johnson (Janssen) (1) Sanofi (1) argenx (1) UCB Biopharma SRL (1) Thomas Jefferson University (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.